Clinical trial IJB_2732
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/1b |
Academic trial | Non |
Sponsor | Lilly |
EudraCT Identifier | 2017-002693-39 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03343613 |
Inclusion criteria | Metastatic Biopsy mandatory |
Last update |